会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • SIZE-BASED GENOMIC ANALYSIS
    • 基于大小的基因分析
    • WO2011054936A1
    • 2011-05-12
    • PCT/EP2010/066935
    • 2010-11-05
    • THE CHINESE UNIVERSITY OF HONG KONGLO, Yuk Ming DennisCHAN, Kwan CheeZHENG, WenliCHIU, Wai Kwun Rossa
    • LO, Yuk Ming DennisCHAN, Kwan CheeZHENG, WenliCHIU, Wai Kwun Rossa
    • C12Q1/68
    • C12Q1/6883C12Q1/6809C12Q2600/112C12Q2600/156C12Q2600/172G06F19/18
    • Systems, methods, and apparatuses for performing a prenatal diagnosis of a sequence imbalance are provided. A shift (e.g. to a smaller size distribution) can signify an imbalance in certain circumstances. For example, a size distribution of fragments of nucleic acids from an at-risk chromosome can be used to determine a fetal chromosomal aneuploidy. A size ranking of different chromosomes can be used to determine changes of a rank of an at- risk chromosome from an expected ranking. Also, a difference between a statistical size value for one chromosome can be compared to a statistical size value of another chromosome to identify a significant shift in size. A genotype and haplotype of the fetus may also be determined using a size distribution to determine whether a sequence imbalance occurs in a maternal sample relative to a genotypes or haplotype of the mother, thereby providing a genotype or haplotype of the fetus.
    • 提供了用于执行序列不平衡的产前诊断的系统,方法和装置。 在某些情况下,偏移(例如,到更小的分布)可以表示不平衡。 例如,可以使用来自高危染色体的核酸片段的大小分布来确定胎儿染色体非整倍体。 可以使用不同染色体的大小排序来从预期排名中确定危险染色体等级的变化。 而且,一个染色体的统计大小值之间的差异可以与另一个染色体的统计大小值进行比较,以确定大小的显着变化。 也可以使用大小分布来确定胎儿的基因型和单倍型,以确定相对于母体的基因型或单倍型,母体样品中是否发生序列不平衡,从而提供胎儿的基因型或单倍型。
    • 6. 发明申请
    • CIRCULATING MRNA AS DIAGNOSTIC MARKERS FOR PREGNANCY-RELATED DISORDERS
    • 将MRNA作为诊断标记循环用于与PREGNNC相关的疾病
    • WO2004065629A1
    • 2004-08-05
    • PCT/GB2004/000145
    • 2004-01-16
    • THE CHINESE UNIVERSITY OF HONG KONGLO, Yuk-Ming DennisNG, Kai OnTSUI, Bo YinCHIU, Wai Kwun Rossa
    • LO, Yuk-Ming DennisNG, Kai OnTSUI, Bo YinCHIU, Wai Kwun Rossa
    • C12Q1/68
    • C12Q1/6883C12Q2600/156C12Q2600/158
    • Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin β subunit (hCG-β), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin β subunit (hCG-β), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.
    • 提供方法和试剂盒,用于诊断,监测或预测怀孕妇女的pre-eclaimpsia,胎儿染色体非整倍性和早产儿的状况,以及通过定量测量孕妇血液中的孕妇检测怀孕情况 编码人绒毛膜促性腺激素β亚基(hCG-β),人胎盘乳腺癌(hPL),促皮质激素释放激素(hCRH),KiSS-1转移抑制因子(KISS1),组织因子途径抑制剂2 (TPFI2),胎盘特异性1(PLAC1)或甘油醛-3-磷酸脱氢酶(GAPDH),并比较方法和试剂盒的数量用于诊断,监测或预测前期症状,胎儿染色体 非整倍体和孕妇的早产,以及检测女性的怀孕,通过定量测量母体血液中编码人绒毛膜促性腺激素的一种或多种mRNA种类的数量为 (hCG-β),人胎盘乳腺癌(hPL),促皮质激素释放激素(hCRH),KiSS-1转移抑制因子(KISS1),组织因子途径抑制剂2(TPFI2),胎盘特异性1(PLAC1) 或甘油醛-3-磷酸脱氢酶(GAPDH),并将mRNA种类的量与标准对照进行比较。
    • 9. 发明申请
    • NONINVASIVE PRENATAL DIAGNOSIS OF FETAL TRISOMY BY ALLELIC RATIO ANALYSIS USING TARGETED MASSIVELY PARALLEL SEQUENCING
    • 通过使用特定的大规模并行序列的ALLELIC比率分析对非局部性TRISOMY进行无意义的初步诊断
    • WO2013150503A1
    • 2013-10-10
    • PCT/IB2013/052804
    • 2013-04-08
    • THE CHINESE UNIVERSITY OF HONG KONG
    • CHIU, Wai Kwun RossaLIAO, JiaweiCHAN, Kwan CheeLO, Yuk Ming Dennis
    • C12Q1/68
    • C12Q1/6883C12Q1/6827C12Q2600/156C12Q2600/158G06F19/20G06F19/22C12Q2537/16
    • Whether a fetus has an aneuploidy associated with a first chromosome is detected using ratios of alleles detected in a maternal sample having a mixture of maternal and fetal DNA. DNA from the sample is enriched for target regions associated with polymorphic loci and then sequenced. Polymorphic loci (e.g., single nucleotide polymorphisms) in the target regions with fetal -specific alleles are identified on a first chromosome and on one or more reference chromosomes. A first ratio of the fetal-specific alleles and shared alleles is determined for the loci on the first chromosome. A second ratio of the fetal-specific alleles and shared alleles is determined for the loci on the reference chromosome(s). A third ratio of the first and second ratio can be compared to a cutoff to determine whether an aneuploidy is present, and whether die aneuploidy is maternally-derived or paternally-derived.
    • 使用在具有母体和胎儿DNA混合物的母体样品中检测到的等位基因的比例来检测胎儿是否具有与第一染色体相关联的非整倍体。 来自样品的DNA富集与多态性位点相关的靶区域,然后测序。 在具有胎儿特异性等位基因的靶区域中的多态性位点(例如,单核苷酸多态性)在第一染色体上和一个或多个参考染色体上鉴定。 确定第一染色体上的位点的胎儿特异性等位基因和共享等位基因的第一比例。 针对参考染色体上的位点确定胎儿特异性等位基因和共享等位基因的第二比例。 可以将第一和第二比率的第三比值与截止值进行比较,以确定是否存在非整倍体,并且是否将非整倍体的母体衍生或亲本衍生。